Market Cap (In USD)
31.89 Million
Revenue (In USD)
-
Net Income (In USD)
-8.2 Million
Avg. Volume
6666.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.23-3.3
- PE
- -
- EPS
- -
- Beta Value
- -1.01
- ISIN
- US0345691036
- CUSIP
- 034569103
- CIK
- 1815974
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Richard Anthony Cunningham
- Employee Count
- -
- Website
- https://www.anebulo.com
- Ipo Date
- 2021-05-07
- Details
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
More Stocks
-
ANXAnexo Group Plc
ANX
-
GPHOFGraphite One Inc.
GPHOF
-
002242Joyoung Co.,Ltd
002242
-
002782
-
KOTMY
-
SX
-
MCLEMedicale Corp
MCLE
-
CAD